Inactive Instrument
Biosyent Inc. Stock Toronto S.E.
Stocks
RX
CA0906901081
Pharmaceuticals
OTC Markets Traded| Market Cap | 165M 116M 102M 93.74M 86.89M 11.03B 168M 1.12B 437M 5.44B 436M 427M 18.82B | P/E 2026 * |
16.2x | P/E 2027 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise Value | 165M 116M 102M 93.74M 86.89M 11.03B 168M 1.12B 437M 5.44B 436M 427M 18.82B | EV / Sales 2026 * |
2.39x | EV / Sales 2027 * | 2x |
| Free-Float |
65.09% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Biosyent Inc.
| 1 day | +0.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.37% | +3.88% | - | - | 116M | |
| +2.96% | +3.01% | +59.87% | +173.31% | 1,102B | |
| +3.05% | +5.23% | +72.11% | +67.81% | 643B | |
| -0.04% | +1.20% | +35.72% | +87.93% | 450B | |
| +0.98% | -2.07% | +27.62% | +22.57% | 336B | |
| -0.73% | -0.62% | +28.88% | +48.16% | 288B | |
| -2.47% | +1.18% | -27.86% | -40.73% | 222B | |
| +0.45% | +1.65% | +25.65% | +68.35% | 199B | |
| +5.21% | +7.93% | +21.99% | +83.23% | 169B | |
| +1.48% | -0.04% | -4.64% | -32.25% | 137B | |
| Average | +0.33% | +2.00% | +26.59% | +53.15% | 393.9B | |
| Weighted average by Cap. | +0.09% | +1.86% | +41.75% | +87.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 48.62M 42.55M 39.22M 36.35M 4.61B 70.11M 470M 183M 2.28B 183M 179M 7.87B | 82.3M 58M 50.75M 46.77M 43.35M 5.5B 83.63M 561M 218M 2.72B 218M 213M 9.39B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Choose MarketScreener 
